AbbVie, J&J to add proprietary data to AI protein model in bid to accelerate drug discovery

The AISB Network launches AISB Bind, a new federated initiative through which AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson, will collaboratively train an AI model to predict how small molecules bind to their protein targets

Five pharma companies fine-tuned OpenFold3 Preview 2 across 20,167 private structures, none of which left their environments. On 1,056 held-out structures, high-quality interface predictions rose from 35.6% to 52.1% and correct ligand poses from 28.9% to 46.8%, ahead of every public model. A first for federated drug discovery.

GEN published a thoughtful coverage of last month's Bio-IT World plenary keynote where JT from Apheris presented a session on federated learning and fine-tuning for drug discovery.